Corcept.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD, and by chief medical officer Robert S. Fishman, MD. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update. November 1, 2023. Corcept Appoints Monica Tellado as President, Emerging Markets. October 26, 2023. Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 25, 2023.Company Type For Profit. Contact Email [email protected]. Phone Number 16503273218. Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol ...Apr 7, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Corcept Therapeutics is committed to improving patient lives through the discovery and development of drugs that address serious unmet medical needs related to ...Corcept Celebrates Hispanic Trailblazers During this Hispanic Heritage Month, we honor Dr. Bernardo Alberto Houssay (1887-1971), one of three Argentinians to receive the Nobel Prize in physiology ... Read Our Latest Stock Report on Corcept Therapeutics. Corcept Therapeutics Stock Performance. CORT stock opened at $25.97 on Monday. Corcept Therapeutics has a one year low of $17.86 and a one ...Web

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.

Clinical Trials. View Corcept Therapeutics clinical trials, research and pipeline information for compounds such as CORT118335, CORT125281, and more.Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...A class action complaint has been filed against Corcept, which alleges that defendants made materially false and/or misleading statements, and failed to ...8/3/2022. Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2022. First.WebJustia - Patents - Patents and Patent Application Resources.

Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us!

Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as diabetes, cancer, and depression.

The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol.Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness. …WebSep 9, 2021 · Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ... Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Additional Information Regarding the ...Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Web

Sep 30, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ... 27 Des 2021 ... The case arose incident to ANDA litigation between the parties involving Corcept's Korlym product comprising the active pharmaceutical ...Corcept Therapeutics | 21,335 followers on LinkedIn. Pioneering the discovery and development of cortisol modulators. | Leading the field in the discovery of drugs that modulate the effects of ...Corcept sued Teva in New Jersey in 2018, alleging its proposed generic version of Korlym infringed the patent and others, in a case that is still ongoing. Teva asked the Patent Trial and Appeal ...Webstudy CORT125134-451 (NCT02804750) are supported by Corcept Therapeutics. Editorial support was provided by Tina K. Schlafly of Corcept Therapeutics. Funding for design and production support for this poster was provided by Corcept to MedVal Scientific Information Services (Princeton, NJ). TheCorcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million, compared to $69.8 million in the third quarter of 2022, due to increased clinical trial activity and expenses to support the expansion of our clinical development and commercial ...Research Corcept Therapeutics' (Nasdaq:CORT) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance ...

Corcept Therapeutics is developing next-generation, selective glucocorticoid receptor II (GR II) antagonists for the treatment of psychiatric disorders and.Dec 8, 2022 · Since 2012, Corcept has made Korlym available as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with glucose intolerance or diabetes mellitus type 2 who have failed surgery or are not candidates for surgery. Korlym was the first FDA-approved treatment for that illness. About Corcept

Sep 30, 2021 · Corcept holds patents covering the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders ... Feb 13, 2023 · Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers. About Corcept Therapeutics 27 Des 2021 ... The case arose incident to ANDA litigation between the parties involving Corcept's Korlym product comprising the active pharmaceutical ...Corcept sued Teva in New Jersey in 2018, alleging its proposed generic version of Korlym infringed the patent and others, in a case that is still ongoing. Teva asked the Patent Trial and Appeal ...Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ...WebThe physician should contact Corcept to make the request on behalf of the patient. Physicians may request information about how to apply for access to Corcept’s investigational medications, contact Corcept at 650-327-3270 or email [email protected]. Corcept will acknowledge receipt of such request within one (1) business day.Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol.

Corcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWeb

Corcept believes that all employees should have the opportunity to participate in the company’s success. We offer competitive salaries, option grants, and a comprehensive benefits program, which covers 100 percent of the premiums for you and your dependents, including. Vacation, sick, and flex-time policies that foster strong work/life balance.

2015-10000 12/17/2015 Closed LATHAM & WATKINS LLP 11104397 11063344 10989897 ETC 2015-10001 Steptoe & Johnson LLP FAP 2258 2015-10002 HemoCue AB K142209Corcept Therapeutics announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after ...MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated CORT, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today …WebCorcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.WebCorcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH). In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s …WebCorcept conducted the drug-drug interaction study de-scribed in Lee, collecting data on co-administration of mif-epristone with a strong CYP3A inhibitor. Based on that data, Corcept sought and received the ’214 patent . The ’214 patent relates to methods of treating Cushing’s syndrome by co-administering mifepristone and a strong CYP3A in-Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ... Corcept Therapeutics overview Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol …Corcept plans to submit these results for presentation at a scientific conference. Corcept will initiate a Phase 2b trial in the fourth quarter to further study this dosing regimen. “Miricorilant is highly active in the liver with a unique mechanism of action and holds great promise for the treatment of NASH,” said Naim Alkhouri , MD ...

--Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by ...On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...Sep 30, 2021 · Corcept holds patents covering the composition of relacorilant and the use of cortisol modulators, including Korlym, in the treatment of patients with hypercortisolism. About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders ... Corcept Therapeutics is engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Corcept’s first approved product, Korlym, inhibits the effects of excess cortisol in patients with hypercortisolism by modulating ...Instagram:https://instagram. options on webullcapitalize reviewsmain sewer line replacement insuranceforex.com leverage amount Justia - Patents - Patents and Patent Application Resources.Mar 6, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ... hndl dividendinsurance stocks to buy Jul 17, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements. Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer. kobe lakers apparel Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Additional Information Regarding the ...About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...